P2RY12 and coronary artery disorder: Rather, several studies reported the ability of antiplatelet P2Y12-R antagonists, clopidrogrel and ticagrelor, to improve endothelial functions in different clinical settings such as in patients with stable coronary artery disease (CAD) and type 2 diabetes (TD2) [92,93,94,95,96].